Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC, Pfizer and Infinity Pharmaceuticals
CORAL SPRINGS, Florida, February 20, 2013 /PRNewswire/ --
FinancialNewsMedia.com reports on active HealthCare Companies to watch today: Crown Marketing, Herbalife Ltd. (NYSE: HLF), Novogen Ltd. (NASDAQ: NVGN), GNC Holdings, Inc. (NYSE: GNC), Pfizer Inc. (NYSE: PFE) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI).
Crown Marketing, currently trading on the OTCQB market, traded over 880,000 shares yesterday, exceeding its average daily volume. To see the latest news and charts for Crown, please go to http://www.marketwatch.com/investing/stock/cwnm. News issued this morning from Crown Marketing was the company announced that patents for its Controlled Drug Delivery Technology (CDDT) have been approved and registered in Mexico. Mexico's pharmaceutical industry faces unique challenges. According to an American Enterprise Institute study, Mexico's$15.5 billion market is plagued by counterfeit goods. Illicit activity in Mexico's pharmaceutical industry is estimated at roughly USD 1.9 billion per year-with counterfeiting representing 81 percent of that illicit market. This is a situation where CWNM believes its unique technology could have a significant impact. For more details regarding Crown's CDDT applications, go to http://crowncddt.com/technology/
Herbalife Ltd. (NYSE: HLF) reported late yesterday the company's fourth quarter net sales of $1.1 billion, reflecting an increase of 20 percent compared to the same time period in 2011 on volume point growth of 18 percent. Net income for the quarter of $117.8 million, or $1.05 per diluted share, compares to 2011 fourth quarter net income of $105.4 million and EPS of $0.86, respectively. Herbalife shares soared yesterday in trading after documents revealed corporate raider Carl Icahn's huge stake in the Los Angeles-based maker of nutritional foods and supplements. Shortly after the opening bell on Wall Street yesterday, Herbalife shares added $4.72, or 12.3%, to $42.99, closing at $39.74.
Novogen Ltd. (NASDAQ: NVGN) experience heavy trading in the markets yesterday closing up over 200% on 2.29Million shares traded. Novogen uses a virtual model in its approach to drug discovery and development. The new lean corporate structure focuses on its human capital in-place of expensive facilities and equipment that can be outsourced. The drug discovery strategies and plans are created in-house then executed by a number of leading external research organizations. This affords Novogen immediate access to cutting edge facilities, skills, equipment and scale-up processes. This strategy drives efficiencies over the drug discovery/development continuum.
GNC Holdings, Inc. (NYSE: GNC), hit a new 52-week high Tuesday as it is closed at $42.19, above its previous 52-week high with over 3.9 million shares traded as of the close. Average volume has been two million shares over the past 30 days. GNC, the nation's largest specialty retailer of health and wellness products, announced yesterday that its employees and customers donated a total of $3.1 million during these past few months to support the St. Jude Children's Research Hospital Thanks and Giving campaign. The campaign, now in its ninth year, builds awareness of and raises funds for the lifesaving research and treatment done at St. Jude to help children fighting cancer and other deadly diseases.
Pfizer Inc. (NYSE: PFE), a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. Pfizer pushed the pharma industry higher in trading yesterday making a featured drugs winner for the day. By the end of trading, Pfizer rose 42 cents (1.5%) to $27.71 on average volume. Throughout the day, 28.4 million shares of Pfizer exchanged hands as compared to its average daily volume of 32.5 million shares. The stock ranged in a price between $27.38-$27.71 after having opened the day at $27.40 as compared to Friday's trading day's close of $27.29.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is an innovative drug discovery and development company seeking to discover, develop and deliver to patients best-in-class medicines for diseases with significant unmet need. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity Pharmaceuticals' shares spiked 16 percent Tuesday after Morgan Stanley issued a bullish assessment of the Cambridge-based company's prospects and pricing potential. As of Tuesday, Morgan Stanley was promoting an "Overweight" recommendation to investors in Infinity stock while also assigning the company a $47 price-per-share target. Infinity (Nasdaq: INFI) saw its stock rise to $41.48 a share yesterday before closing at $41.10
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.